Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


‘Business of science’ digest—October 2021

Business trading graphic

Credit: 29mokara/iStock/Thinkstock

Pfizer buys Trillium and its CD47 candidates for US$2.3 billion

Interest in macrophage biology remains strong, shows Pfizer’s acquisition of Trillium Therapeutics, a company with two clinical-stage CD47-targeting candidates.

Nature Reviews Drug Discovery

Evolution of the market for mRNA technology

2020 was a breakout year for mRNA technology platforms with the launch and widespread use of mRNA vaccines for COVID-19. This article forecasts the potential of this growing market.

Nature Reviews Drug Discovery

A novel single-agent antibiotic

Antimicrobial resistance is a substantial public health challenge, and new antibiotics — especially those that target drug-resistant Gram-negative pathogens — are needed.

Nature Reviews Drug Discovery

India’s DNA COVID vaccine is a world first – more are coming

The ZyCoV-D vaccine heralds a wave of DNA vaccines for various diseases that are undergoing clinical trials around the world.


The fight to manufacture COVID vaccines in lower-income countries

Drug companies and wealthy countries are facing increased pressure to partner with firms in the global south but are reluctant to relinquish control.


Greece used AI to curb COVID: what other nations can learn

Governments are hungry to deploy big data in health emergencies and scientists must help to lay the legal, ethical and logistical groundwork. This article explores how Greece employed a machine-learning algorithm to determine which travellers entering the country should be tested for COVID-19.


Novel drug therapies could tackle treatment-resistant depression

An anesthetic, a steroid and a psychedelic are new treatments for a devastating psychiatric disorder.

Scientific American


Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links